Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Youths - Birth - 17
  • Ohio
  • Cleveland


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Testing TRUST Depression Management Intervention
    NCT03599141
    Conditions:   Depression;   Quality of Life
    Interventions:   Behavioral: Trust-building Self-management Together;   Behavioral: Depression Management
    Sponsors:   Case Western Reserve University;   National Institute on Minority Health and Health Disparities (NIMHD)
    Recruiting
  • Promote Access to Stop Suicide: Comparison of Follow up Services for Youth at Risk for Suicide
    NCT03016572
    Conditions:   Suicide;   Depressive Disorder, Major;   Anxiety Disorders;   Suicidal Ideation;   Suicidal Impulses
    Interventions:   Behavioral: Standard of Care;   Behavioral: Crisis Intervention;   Behavioral: Wraparound Services
    Sponsors:   The Cleveland Clinic;   Case Western Reserve University
    Recruiting
  • Biomarkers as Predictors of Suicidal Risk in Adolescents
    NCT03014518
    Conditions:   Suicide, Attempted;   Suicidal Ideation;   Suicidal Intention;   Suicide
    Interventions:   Other: Clinical assessments and blood samples; follow-up for 12 mos;   Other: Clinical assessments and blood samples; no 12mo follow-up
    Sponsors:   The Cleveland Clinic;   Case Western Reserve University;   Van Andel Research Institute;   National Institute of Mental Health (NIMH)
    Recruiting
  • CyberCycling to Reduce Therapeutic Side Effects and Improve Quality of Life in AYA Cancers
    NCT02916472
    Condition:   Adolescent and Young Adult Cancers
    Interventions:   Behavioral: CyberCycling;   Behavioral: Stretching;   Behavioral: Resistance Bands
    Sponsor:   Case Comprehensive Cancer Center
    Recruiting
  • Restoring High Dimensional Hand Function to Persons With Chronic High Tetraplegia
    NCT03482310
    Conditions:   Spinal Cord Injuries;   Tetraplegia;   Quadriplegia
    Intervention:   Device: Using the Neuroport cortical recording array to determine the desired grasp pattern for a functional electrical stimulation (FES) system
    Sponsors:   VA Office of Research and Development;   Case Western Reserve University
    Recruiting
  • Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma
    NCT03467789
    Conditions:   Basal Cell Carcinoma;   Basal Cell Nevus Syndrome
    Interventions:   Dietary Supplement: Vitamin D3 prior to first visit;   Dietary Supplement: Vitamin D3 prior to second visit;   Radiation: Photodynamic therapy;   Dietary Supplement: Maintenance Vitamin D3
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Getting Ahead for Cancer Control
    NCT03247634
    Condition:   Cancer Prevention
    Intervention:   Behavioral: Getting Ahead in a Just-Gettin'-By World
    Sponsor:   Case Comprehensive Cancer Center
    Recruiting
  • Comparing the Efficacy of Epidural and Quadratus Lumborum Analgesia After Open Nephrectomy Surgery
    NCT03110081
    Condition:   Open Nephrectomy Surgery
    Interventions:   Procedure: Quadratus lumborum block;   Procedure: Epidural analgesia
    Sponsor:   The Cleveland Clinic
    Recruiting
  • ACTHAR Therapy for Central Nervous System Sarcoidosis
    NCT02920710
    Condition:   Sarcoidosis
    Intervention:   Drug: Repository Corticotropin Injection
    Sponsors:   The Cleveland Clinic;   Mallinckrodt
    Recruiting
  • Genetics of Uveitis
    NCT02357238
    Conditions:   Uveitis;   Infectious Uveitis
    Intervention:  
    Sponsor:   The Cleveland Clinic
    Recruiting
  • Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography
    NCT01746537
    Condition:   Uveitis
    Intervention:  
    Sponsor:   The Cleveland Clinic
    Recruiting
  • Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
    NCT03104491
    Condition:   Cluster of Differentiation Antigen (CD22)-Positive Acute Lymphoblastic Leukemia
    Intervention:   Drug: Inotuzumab Ozogamicin
    Sponsor:   Leland Metheny
    Recruiting
  • Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
    NCT01951885
    Conditions:   Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Biphenotypic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Hodgkins Disease;   Chronic Lymphocytic Leukemia;   Multiple Myeloma
    Interventions:   Drug: tacrolimus;   Drug: methotrexate;   Drug: Mycophenolate mofetil;   Drug: Methotrexate (low dose)
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Project Guard: Reducing Alcohol Misuse/Abuse in the National Guard
    NCT02860442
    Condition:   Alcohol Use
    Interventions:   Behavioral: Smartphone brief intervention (SP-BI);   Other: Enhanced Usual Care (EUC)
    Sponsors:   Joseph Calabrese, MD;   Case Western Reserve University;   University of Michigan;   University of Toledo Health Science Campus
    Recruiting
  • Vitamin D and Photodynamic Therapy for Treatment of BCC in BCNS
    NCT03483441
    Conditions:   Basal Cell Nevus Syndrome;   Basal Cell Carcinoma
    Interventions:   Other: Placebo pill;   Dietary Supplement: Vitamin D;   Drug: PDT
    Sponsors:   The Cleveland Clinic;   University of Arizona;   Harvard Medical School
    Recruiting
  • Comparative Effectiveness of EIBI and Adaptive ABA for Children With Autism
    NCT04078061
    Condition:   Autism Spectrum Disorder
    Interventions:   Behavioral: MABA;   Behavioral: EIBI
    Sponsors:   University of Rochester;   The Cleveland Clinic;   May Institute;   Nationwide Children's Hospital;   Vanderbilt University Medical Center;   University of Michigan;   University of Virginia
    Recruiting
  • Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
    NCT03383575
    Conditions:   Acute Myeloid Leukemia;   Blasts 20-30 Percent of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia;   IDH2 Gene Mutation;   Myelodysplastic Syndrome With Excess Blasts;   Recurrent High Risk Myelodysplastic Syndrome;   Refractory High Risk Myelodysplastic Syndrome
    Interventions:   Drug: Azacitidine;   Drug: Enasidenib;   Other: Quality-of-Life Assessment
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   Celgene
    Recruiting
  • Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
    NCT04009668
    Conditions:   FSGS;   MCD;   Focal Segmental Glomerulosclerosis;   Minimal Change Disease
    Intervention:   Drug: adalimumab
    Sponsors:   University of Michigan;   New York University
    Recruiting
  • A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants
    NCT03979313
    Condition:   Respiratory Syncytial Virus Infections
    Interventions:   Drug: MEDI8897;   Drug: Placebo
    Sponsor:   MedImmune LLC
    Recruiting
  • Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects
    NCT03721965
    Condition:   Acute Graft-versus-host Disease
    Interventions:   Drug: Itacitinib;   Drug: Corticosteroids
    Sponsor:   Incyte Corporation
    Recruiting
  • Sentinel Low Risk Registry
    NCT04131127
    Condition:   To Determine the Incidence and Type of Debris Capture in SENTINEL Devices Deployed During TAVI in Patients at Low Surgical Risk
    Intervention:   Device: Sentinel Device
    Sponsors:   CVPath Institute Inc.;   Boston Scientific Corporation
    Recruiting
  • HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors
    NCT02875314
    Conditions:   Medulloblastoma;   Central Nervous System Embryonal Tumors
    Interventions:   Drug: Induction;   Drug: Single Cycle Intensive Chemotherapy;   Drug: Tandem 3 Cycle Intensive Chemotherapy
    Sponsors:   Nationwide Children's Hospital;   Children's Hospital Los Angeles
    Recruiting
  • National Collaborative to Improve Care of Children With Complex Congenital Heart Disease
    NCT02852031
    Condition:   Hypoplastic Left Heart Syndrome (HLHS)
    Intervention:   Other: Collaborative Learning Network
    Sponsor:   Children's Hospital Medical Center, Cincinnati
    Recruiting
  • Dextromethorphan Pediatric Acute Cough Study
    NCT02651116
    Condition:   Cough
    Interventions:   Drug: Dextromethorphan Hydrobromide;   Drug: Placebo;   Device: Cough recording device
    Sponsor:   Pfizer
    Recruiting
  • Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
    NCT02521493
    Conditions:   Acute Myeloid Leukemia;   Down Syndrome;   Myelodysplastic Syndrome;   Myeloid Leukemia Associated With Down Syndrome;   Myeloproliferative Neoplasm
    Interventions:   Drug: Asparaginase;   Drug: Asparaginase Erwinia chrysanthemi;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone;   Drug: Mitoxantrone Hydrochloride;   Drug: Thioguanine
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Apixaban for the Acute Treatment of Venous Thromboembolism in Children
    NCT02464969
    Condition:   Venous Thromboembolism
    Interventions:   Drug: Apixaban;   Drug: Standard of Care
    Sponsors:   Pfizer;   Bristol-Myers Squibb
    Recruiting
  • A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
    NCT02369653
    Conditions:   Lymphoma;   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Apixaban;   Other: No systemic anticoagulant prophylaxis
    Sponsors:   Bristol-Myers Squibb;   Pfizer
    Recruiting
  • Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
    NCT02176967
    Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Neuroblastoma
    Interventions:   Drug: Carboplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Healthy Sleep for Children With Down Syndrome
    NCT03922165
    Conditions:   Down Syndrome;   Sleep Disordered Breathing
    Intervention:   Procedure: Adenotonsillectomy
    Sponsors:   Brigham and Women's Hospital;   Children's Hospital of Philadelphia;   University Hospitals Cleveland Medical Center;   Children's Hospital Medical Center, Cincinnati;   University of Michigan;   University of Texas Southwestern Medical Center;   University of Rochester;   Children's Hospital of The King's Daughters
    Recruiting
  • Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
    NCT03067181
    Conditions:   Childhood Extracranial Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Germ Cell Tumor;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
    Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
    NCT02867592
    Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • DOSE Trial of Opioid Sparing Effect
    NCT03938857
    Conditions:   Dexmedetomidine;   Mechanical Ventilation Complication;   Critically Ill
    Interventions:   Drug: Fentanyl;   Drug: Dexmedetomidine
    Sponsors:   Duke University;   National Institutes of Health (NIH);   Johns Hopkins University;   Intermountain Health Care, Inc.;   Vanderbilt University Medical Center
    Recruiting
  • A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy
    NCT03914625
    Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Down Syndrome
    Interventions:   Drug: Asparaginase Erwinia chrysanthemi;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Mercaptopurine Oral Suspension;   Drug: Methotrexate;   Drug: Prednisolone;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Hydroxyurea Optimization Through Precision Study
    NCT03789591
    Conditions:   Sickle Cell Disease;   Sickle Cell Anemia
    Intervention:   Drug: Hydroxyurea
    Sponsors:   Children's Hospital Medical Center, Cincinnati;   Doris Duke Charitable Foundation
    Recruiting
  • Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
    NCT03709680
    Conditions:   Solid Tumors;   Ewing Sarcoma;   Rhabdoid Tumor;   Rhabdomyosarcoma;   Neuroblastoma;   Medulloblastoma;   Diffuse Intrinsic Pontine Glioma
    Interventions:   Drug: Palbociclib;   Drug: Temozolomide;   Drug: Irinotecan
    Sponsor:   Pfizer
    Recruiting
  • Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
    NCT03581292
    Conditions:   Anaplastic Astrocytoma;   Glioblastoma;   Malignant Glioma
    Interventions:   Radiation: Radiation Therapy;   Drug: Temozolomide;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
    NCT03533582
    Conditions:   Childhood Hepatocellular Carcinoma;   Childhood Malignant Liver Neoplasm;   Hepatoblastoma;   Hepatocellular Malignant Neoplasm, Not Otherwise Specified;   SMARCB1 Gene Mutation
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Irinotecan;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Other: Patient Observation;   Drug: Sorafenib;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
    NCT03213704
    Conditions:   Advanced Malignant Solid Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Wilms Tumor
    Interventions:   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
    NCT03213678
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Samotolisib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
    NCT03155620
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Langerhans Cell Histiocytosis;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
    Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Ensartinib;   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Drug: Palbociclib;   Other: Pharmacological Study;   Drug: Samotolisib;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Ulixertinib;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma
    NCT03126916
    Conditions:   Ganglioneuroblastoma;   INRG Stage L2;   INRG Stage M;   INRG Stage MS;   Neuroblastoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Drug: Melphalan;   Drug: Melphalan Hydrochloride;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan;   Drug: Topotecan Hydrochloride;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
    NCT03007147
    Conditions:   B Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University of Milano Bicocca
    Recruiting
  • Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
    NCT02724579
    Conditions:   CTNNB1 Gene Mutation;   Medulloblastoma;   Wnt Positive
    Interventions:   Drug: Cisplatin;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Lomustine;   Radiation: Radiation Therapy;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
    NCT02723994
    Condition:   Leukemia
    Interventions:   Drug: Ruxolitinib;   Drug: Asparaginase Erwinia Chrysanthemi;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Incyte Corporation;   Children's Oncology Group
    Recruiting
  • Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
    NCT02567435
    Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma
    Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)
    NCT02776735
    Condition:   Juvenile Idiopathic Arthritis
    Intervention:   Drug: Sarilumab
    Sponsors:   Sanofi;   Regeneron Pharmaceuticals
    Recruiting
  • A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Balovaptan in Children With Autism Spectrum Disorder
    NCT04049578
    Condition:   Autism Spectrum Disorder
    Intervention:   Drug: Balovaptan
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Pediatric Adenotonsillectomy Trial for Snoring
    NCT02562040
    Condition:   Sleep-Disordered Breathing
    Interventions:   Procedure: Early Adenotonsillectomy (eAT);   Behavioral: Watchful Waiting with Supportive Care (WWSC)
    Sponsors:   Brigham and Women's Hospital;   Children's Hospital of Philadelphia;   University Hospitals Cleveland Medical Center;   Children's Hospital Medical Center, Cincinnati;   University of Michigan;   University of Texas Southwestern Medical Center;   University of Rochester;   Children's Hospital of The King's Daughters;   Boston Children’s Hospital
    Recruiting
  • Study Evaluating PK/PD and Safety of Betrixaban in Pediatric Patients
    NCT03346083
    Condition:   VTE Prophylaxis
    Intervention:   Drug: Betrixaban
    Sponsor:   Portola Pharmaceuticals
    Recruiting
  • A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)
    NCT03905330
    Condition:   Progressive Familial Intrahepatic Cholestasis (PFIC)
    Interventions:   Drug: Maralixibat;   Other: Placebo
    Sponsor:   Mirum Pharmaceuticals, Inc.
    Recruiting
  • A Safety and PK Study of IV Eravacycline
    NCT03696550
    Condition:   Bacterial Infections
    Intervention:   Drug: Eravacycline (TP-434)
    Sponsor:   Tetraphase Pharmaceuticals, Inc.
    Recruiting
  • Hospital-Based Cluster Trial: Magnetically Controlled Growing Rods Using Distraction Intervals
    NCT04058561
    Condition:   Early-Onset Scoliosis Deformity of Spine
    Intervention:   Device: MAGEC® Spinal Bracing And Distraction System
    Sponsors:   Children's Spine Foundation;   Columbia University
    Recruiting
  • A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children
    NCT03959488
    Condition:   Respiratory Syncytial Virus Infections
    Interventions:   Drug: MEDI8897;   Drug: Palivizumab
    Sponsor:   MedImmune LLC
    Recruiting
  • Efficacy and Safety of Erenumab in Pediatric Subjects With Episodic Migraine
    NCT03836040
    Condition:   Migraine
    Interventions:   Drug: Erenumab Dose 1;   Drug: Erenumab Dose 2;   Drug: Erenumab Dose 3;   Other: Placebo
    Sponsor:   Amgen
    Recruiting
  • Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
    NCT03832998
    Condition:   Migraine
    Interventions:   Drug: Erenumab Dose 1;   Drug: Erenumab Dose 2;   Drug: Erenumab Dose 3;   Other: Placebo
    Sponsor:   Amgen
    Recruiting
  • Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:
    NCT02616484
    Condition:   Pyruvate Dehydrogenase Complex Deficiency
    Interventions:   Drug: Dichloroacetate (DCA);   Other: Placebo;   Genetic: Genotype
    Sponsors:   University of Florida;   Columbia University;   Medosome Biotec LLC;   Saol Therapeutics
    Recruiting
  • Study of Pediatric Migraine: The Pediatric Migraine Registry
    NCT03742024
    Condition:   Migraine
    Intervention:  
    Sponsors:   Duke University;   University of California, San Francisco
    Recruiting
  • Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age
    NCT03691779
    Condition:   Cystic Fibrosis
    Interventions:   Drug: VX-445;   Drug: TEZ;   Drug: IVA
    Sponsor:   Vertex Pharmaceuticals Incorporated
    Recruiting
  • Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects With Tourette's Disorder
    NCT03661983
    Condition:   Tourette's Disorder (TD)
    Interventions:   Drug: Aripiprazole (OPC-14597);   Drug: Placebo
    Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
    Recruiting
  • Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV
    NCT03636906
    Condition:   Respiratory Syncytial Virus Infections
    Interventions:   Biological: Respiratory syncytial virus (RSV) vaccine GSK3389245A;   Biological: Bexsero;   Biological: Nimenrix;   Biological: Menveo;   Biological: Synflorix;   Drug: Placebo
    Sponsor:   GlaxoSmithKline
    Recruiting
  • Management of the PDA Trial
    NCT03456336
    Conditions:   Infant, Premature;   Patent Ductus Arteriosus;   Infant, Newborn, Diseases;   Patent Ductus Arteriosus After Premature Birth
    Interventions:   Other: Active Treatment;   Other: Expectant Management
    Sponsor:   NICHD Neonatal Research Network
    Recruiting
  • Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
    NCT03429543
    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: Linagliptin;   Drug: Empagliflozin;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim
    Recruiting
  • Moderately Preterm Infants With Caffeine at Home for Apnea (MoCHA) Trial
    NCT03340727
    Condition:   Apnea of Prematurity
    Interventions:   Drug: Caffeine Citrate;   Drug: Placebo
    Sponsors:   NICHD Neonatal Research Network;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting
  • Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia in First Remission
    NCT03223753
    Condition:   Acute Lymphoblastic Leukemia in Remission
    Interventions:   Other: Educational Intervention;   Other: Internet-Based Intervention;   Other: Laboratory Biomarker Analysis;   Device: Monitoring Device;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age
    NCT03211247
    Condition:   Peanut Allergy
    Interventions:   Biological: Viaskin Peanut 250 mcg;   Biological: Viaskin Peanut 100 mcg;   Biological: Placebo
    Sponsor:   DBV Technologies
    Recruiting
  • Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide
    NCT03185819
    Condition:   Depressive Disorder, Major
    Interventions:   Drug: Intranasal Placebo;   Drug: Midazolam Placebo Solution;   Drug: Midazolam;   Drug: Esketamine
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)
    NCT03182907
    Condition:   Clostridium Difficile Infection
    Interventions:   Biological: Bezlotoxumab;   Drug: Placebo
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  • A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus
    NCT03170518
    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: Canagliflozin 100 mg;   Drug: Canagliflozin 300 mg;   Drug: Placebo
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
    NCT03138655
    Conditions:   Ulcerative Colitis;   Crohn's Disease
    Intervention:   Drug: Vedolizumab
    Sponsor:   Takeda
    Recruiting
  • A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
    NCT02932410
    Condition:   Pulmonary Arterial Hypertension
    Interventions:   Drug: Macitentan;   Other: Standard-of-care
    Sponsor:   Actelion
    Recruiting
  • Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease
    NCT02850406
    Condition:   Sickle Cell Disease
    Intervention:   Drug: GBT440
    Sponsor:   Global Blood Therapeutics
    Recruiting
  • Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
    NCT02828358
    Conditions:   Acute Leukemia of Ambiguous Lineage;   B Acute Lymphoblastic Leukemia;   Mixed Phenotype Acute Leukemia
    Interventions:   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisolone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Pediatric ACL: Understanding Treatment Options
    NCT02772770
    Condition:   Anterior Cruciate Ligament Reconstruction
    Interventions:   Other: Non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions;   Procedure: Surgical technique: Transphyseal reconstruction;   Procedure: Surgical technique: Partial transphyseal reconstruction;   Procedure: Surgical technique: Physeal sparing reconstruction by the Anderson method;   Procedure: Surgical technique: Physeal sparing reconstruction by the Micheli/Kocher method
    Sponsors:   Boston Children’s Hospital;   Children's Hospital of Philadelphia;   Children's Hospital Medical Center, Cincinnati;   Rady Children's Hospital, San Diego;   Washington University School of Medicine;   Children's Healthcare of Atlanta;   The Cleveland Clinic;   Tennessee Orthopedic Alliance;   Hospital for Special Surgery, New York;   Stanford University
    Recruiting
  • Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD)
    NCT02709655
    Condition:   Depressive Disorder, Major
    Interventions:   Drug: Vortioxetine 10 mg/day;   Drug: Vortioxetine 20 mg/day;   Drug: Fluoxetine 20mg/day;   Other: Placebo
    Sponsors:   H. Lundbeck A/S;   Takeda
    Recruiting
  • Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure
    NCT02678312
    Condition:   Pediatric Heart Failure
    Interventions:   Drug: LCZ696;   Drug: Enalapril;   Drug: Placebo of LCZ696;   Drug: Placebo of Enalapril
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • BAX 855 Previously Untreated Patient (PUP)
    NCT02615691
    Condition:   Hemophilia A
    Intervention:   Biological: PEGylated Recombinant Factor VIII
    Sponsor:   Baxalta now part of Shire
    Recruiting
  • Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
    NCT02553460
    Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Drug: ITMHA;   Drug: Dexamethasone;   Drug: Mitoxantrone;   Drug: Pegaspargase;   Drug: Asparaginase Erwinia Chrysanthemi;   Drug: Bortezomib;   Drug: Vorinostat;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Leucovorin Calcium;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Vincristine
    Sponsors:   St. Jude Children's Research Hospital;   Gateway for Cancer Research;   Texas Children's Hospital
    Recruiting
  • Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs
    NCT02515773
    Condition:   Bipolar Disorder
    Interventions:   Drug: Metformin;   Behavioral: healthy lifestyle intervention (LIFE)
    Sponsors:   Melissa Delbello;   Patient-Centered Outcomes Research Institute
    Recruiting
  • Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures
    NCT02477839
    Condition:   Epilepsy With Partial-onset Seizures
    Interventions:   Drug: Lacosamide;   Other: Placebo
    Sponsor:   UCB BIOSCIENCES, Inc.
    Recruiting
  • Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
    NCT02141074
    Conditions:   Congenital Bleeding Disorder;   Haemophilia B
    Intervention:   Drug: nonacog beta pegol
    Sponsor:   Novo Nordisk A/S
    Recruiting
  • OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)
    NCT02097121
    Conditions:   Urinary Incontinence;   Urinary Bladder, Overactive
    Intervention:   Biological: OnabotulinumtoxinA
    Sponsor:   Allergan
    Recruiting
  • Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder
    NCT02075047
    Condition:   Bipolar Disorder
    Interventions:   Drug: placebo oral capsules;   Drug: ziprasidone oral capsules
    Sponsor:   Pfizer
    Recruiting
  • Preemie Hypothermia for Neonatal Encephalopathy
    NCT01793129
    Conditions:   Infant, Newborn;   Hypoxia, Brain;   Hypoxia-Ischemia, Brain;   Encephalopathy, Hypoxic-Ischemic;   Hypoxic-Ischemic Encephalopathy;   Ischemic-Hypoxic Encephalopathy
    Interventions:   Device: Hypothermia;   Procedure: Normothermic Control
    Sponsors:   NICHD Neonatal Research Network;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting
  • Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
    NCT04052997
    Conditions:   Relapsed Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
    Intervention:   Drug: Camidanlumab Tesirine
    Sponsor:   ADC Therapeutics S.A.
    Recruiting
  • Generic Database of Very Low Birth Weight Infants
    NCT00063063
    Conditions:   Infant, Newborn;   Infant, Low Birth Weight;   Infant, Small for Gestational Age;   Infant, Premature
    Intervention:  
    Sponsors:   NICHD Neonatal Research Network;   National Center for Research Resources (NCRR);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting
  • Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
    NCT03907488
    Conditions:   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IIIA Hodgkin Lymphoma;   Ann Arbor Stage IIIB Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IVA Hodgkin Lymphoma;   Ann Arbor Stage IVB Hodgkin Lymphoma;   Classic Hodgkin Lymphoma;   Lymphocyte-Rich Classic Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Dacarbazine;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Biological: Filgrastim;   Biological: Nivolumab;   Biological: Pegfilgrastim;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Vinblastine;   Drug: Vinblastine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Axitinib and Nivolumab in Treating Patients With Unresectable or Metastatic TFE/Translocation Renal Cell Carcinoma
    NCT03595124
    Conditions:   Metastatic Renal Cell Carcinoma;   Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Unresectable Renal Cell Carcinoma
    Interventions:   Drug: Axitinib;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Nephrotic Syndrome Study Network
    NCT01209000
    Conditions:   Minimal Change Disease (MCD);   Membranous Nephropathy;   Glomerulosclerosis, Focal Segmental
    Intervention:   Procedure: Kidney Biopsy
    Sponsors:   University of Michigan;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   The NephCure Foundation
    Recruiting
  • A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function
    NCT04038047
    Condition:   Cystic Fibrosis
    Intervention:  
    Sponsors:   David Nichols, MD;   Cystic Fibrosis Foundation
    Recruiting
  • Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
    NCT03794349
    Conditions:   Ganglioneuroblastoma;   Recurrent Neuroblastoma;   Refractory Neuroblastoma
    Interventions:   Biological: Dinutuximab;   Drug: Eflornithine;   Drug: Irinotecan;   Biological: Sargramostim;   Drug: Temozolomide
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
    NCT03635983
    Condition:   Melanoma
    Interventions:   Biological: NKTR-214;   Biological: Nivolumab
    Sponsors:   Bristol-Myers Squibb;   Nektar Therapeutics
    Recruiting
  • An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
    NCT03467958
    Condition:   Crohn Disease
    Intervention:   Drug: Ozanimod
    Sponsor:   Celgene
    Recruiting
  • Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures
    NCT03288129
    Conditions:   Partial Onset Seizures;   Secondarily Generalized Seizures;   Primary Generalized Tonic-Clonic Seizures
    Intervention:   Drug: Perampanel
    Sponsor:   Eisai Inc.
    Recruiting
  • A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
    NCT03112603
    Condition:   Graft-versus-host Disease (GVHD)
    Interventions:   Drug: Ruxolitinib;   Drug: Extracorporeal photopheresis (ECP);   Drug: Low-dose methotrexate (MTX);   Drug: Mycophenolate mofetil (MMF);   Drug: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus);   Drug: Infliximab;   Drug: Rituximab;   Drug: Pentostatin;   Drug: Imatinib;   Drug: Ibrutinib
    Sponsor:   Incyte Corporation
    Recruiting
  • Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI
    NCT02901717
    Condition:   Catheter-related Infections
    Interventions:   Drug: Mino-Lok;   Drug: Antibiotic lock
    Sponsor:   Leonard-Meron Biosciences, Inc.
    Recruiting
  • Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients
    NCT02851407
    Condition:   Veno-occlusive Disease
    Interventions:   Drug: Defibrotide;   Other: Best Supportive Care
    Sponsor:   Jazz Pharmaceuticals
    Recruiting
  • Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
    NCT02392078
    Conditions:   Metastatic Brain Tumor;   Primary Brain Tumor;   Epileptic/Seizure Foci
    Intervention:   Device: NeuroBlate System
    Sponsor:   Monteris Medical
    Recruiting
  • Chronic Hypertension and Pregnancy (CHAP) Project
    NCT02299414
    Condition:   Hypertension
    Interventions:   Drug: Anti-hypertensive therapy;   Other: No anti-hypertensive therapy (unless BP is severe)
    Sponsors:   University of Alabama at Birmingham;   Columbia University;   Drexel University College of Medicine;   Rutgers, The State University of New Jersey;   Lehigh Valley Hospital;   Saint Peters University Hospital;   Christiana Care Health Services;   Washington University School of Medicine;   Duke University;   University of Texas Southwestern Medical Center;   The University of Texas Health Science Center, Houston;   Stanford University;   University of Pennsylvania;   The University of Texas Medical Branch, Galveston;   University of Utah;   Intermountain Health Care, Inc.;   University of California, San Francisco;   Johns Hopkins University;   University of Pittsburgh;   Ochsner Health System;   University of North Carolina, Chapel Hill;   National Heart, Lung, and Blood Institute (NHLBI);   WakeMed Health and Hospitals;   San Francisco General Hospital;   McKay-Dee Hospital;   Winthrop University Hospital;   New York Hospital Queens;   Latter Day Saints Hospital;   Lyndon B Johnson General Hospital;   Virtua Medical Group;   Bayview Medical Center;   Duke Regional Hospital;   Utah Valley Regional Medical Center;   Northwestern;   Brown (WIHRI);   Baylor College of Medicine;   Case Western/Metro Health;   Ohio State University;   University of Iowa;   University of California, San Diego;   Indiana University;   Unity Point Health-Meriter Hospital WI;   Weill Medical College of Cornell University;   University of Oklahoma;   Medical University of South Carolina;   Beaumont Hospital;   University of Colorado, Denver;   University of Kansas Medical Center;   Denver Health and Hospital Authority;   Gundersen Health System;   Aurora Health Care;   Oregon Health and Science University;   Medical College of Wisconsin;   Temple University;   New Jersey Medical School;   University of South Alabama;   Vanderbilt University;   University of Arkansas;   Miami Valley Hospital;   Emory University;   St. Luke's Hospital and Health Network, Pennsylvania;   Cleveland Clinic Fairview Hospital;   University of Tennessee Health Science Center;   TriHealth Inc.;   Cleveland Clinic Hillcrest Hospital;   Tulane University;   Yale University;   Arrowhead Regional Medical Center;   Geisinger Clinic
    Recruiting
  • North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
    NCT01694940
    Conditions:   Mitochondrial Disorders;   Mitochondrial Genetic Disorders;   Mitochondrial Diseases;   Disorder of Mitochondrial Respiratory Chain Complexes;   Deletion and Duplication of Mitochondrial DNA
    Intervention:  
    Sponsors:   Columbia University;   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting
  • Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
    NCT03779854
    Conditions:   Acute Biphenotypic Leukemia;   Acute Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Lymphoblastic Leukemia;   Acute Undifferentiated Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Blasts Under 25 Percent of Bone Marrow Nucleated Cells;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2
    Interventions:   Radiation: Total-Body Irradiation;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Allogeneic Hematopoietic Stem Cell Transplantation (unmanipulated T cell replete BM);   Drug: Tacrolimus;   Drug: Methotrexate;   Biological: Allogeneic Hematopoietic Stem Cell Transplantation (naive T cell-depleted PBSC)
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
    NCT04075266
    Condition:   Multiple Sclerosis
    Intervention:   Drug: Ocrelizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Study of Etelcalceide in Pediatric Subjects With Secondary Hyperparathyroidism and CKD on Hemodialysis
    NCT03633708
    Conditions:   Secondary Hyperparathyroidism;   Chronic Kidney Disease
    Intervention:   Drug: Etelcalcetide
    Sponsor:   Amgen
    Recruiting
  • Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
    NCT03959085
    Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Central Nervous System Leukemia;   Mixed Phenotype Acute Leukemia;   Testicular Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Biological: Inotuzumab Ozogamicin;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
    NCT03919071
    Conditions:   Anaplastic Astrocytoma;   Anaplastic Ganglioglioma;   Anaplastic Pleomorphic Xanthoastrocytoma;   Glioblastoma;   Malignant Glioma;   WHO Grade III Glioma
    Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Radiation: Radiation Therapy;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
    NCT03834961
    Conditions:   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   Central Nervous System Neoplasm;   ETV6 Gene Rearrangement;   Infantile Fibrosarcoma;   NTRK1 Fusion Positive;   NTRK1 Gene Rearrangement;   NTRK2 Fusion Positive;   NTRK2 Gene Rearrangement;   NTRK3 Fusion Positive;   NTRK3 Gene Rearrangement;   Recurrent Acute Leukemia;   Refractory Acute Leukemia;   Solid Neoplasm
    Intervention:   Drug: Larotrectinib
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome
    NCT03649477
    Condition:   Prader-Willi Syndrome
    Interventions:   Drug: intranasal carbetocin Dose 1;   Drug: intranasal carbetocin Dose 2;   Drug: placebo
    Sponsor:   Levo Therapeutics, Inc.
    Recruiting
  • A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)
    NCT03611075
    Condition:   Autism Spectrum Disorder
    Intervention:   Other: No Intervention
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Web Based Orthopaedic Sports Medicine Registry
    NCT01191151
    Conditions:   Degenerative and Traumatic Pathology of the Knee;   Degenerative and Traumatic Pathology of the Shoulder and Elbow;   Degenerative and Traumatic Pathology of the Foot and Ankle;   Degenerative and Traumatic Pathology of the Hand and Wrist;   Degenerative and Traumatic Pathology of the Hip
    Intervention:  
    Sponsor:   Arthrex, Inc.
    Recruiting
  • Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder
    NCT03572933
    Condition:   CDKL5 Deficiency Disorder
    Interventions:   Drug: ganaxolone;   Drug: Placebo
    Sponsor:   Marinus Pharmaceuticals
    Recruiting
  • This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC 1 or 2
    NCT03566238
    Conditions:   PFIC1;   PFIC2
    Interventions:   Drug: A4250 (odevixibat);   Drug: Placebo
    Sponsor:   Albireo
    Recruiting
  • A Pilot Study to Evaluate the Hypoglossal Nerve Stimulator in Adolescents With Down Syndrome and Obstructive Sleep Apnea
    NCT02344108
    Conditions:   Sleep Apnea, Obstructive;   Down Syndrome
    Intervention:   Device: Inspire® Upper Airway Simulation System (Model 3028 IPG )
    Sponsors:   Christopher Hartnick, M.D.;   Massachusetts General Hospital;   University Hospitals Cleveland Medical Center;   Emory University;   Children's Hospital Medical Center, Cincinnati;   Inspire Medical Systems, Inc.;   University of Pittsburgh;   Children's Hospital of The King's Daughters;   University of Texas Southwestern Medical Center;   Texas Children's Hospital;   Oregon Health and Science University;   C.S. Mott Children's Hospital;   Seattle Children's Hospital;   Children's Hospital of Philadelphia
    Recruiting
  • A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome
    NCT03355209
    Condition:   Lennox Gastaut Syndrome
    Interventions:   Drug: ZX008 0.2 or 0.8 mg/kg/day;   Drug: Matching Placebo
    Sponsor:   Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
    Recruiting
  • Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
    NCT03245840
    Condition:   Eosinophilic Esophagitis (EoE)
    Intervention:   Drug: Budesonide oral suspension
    Sponsor:   Shire
    Recruiting
  • Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
    NCT03233204
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Low Grade Glioma;   Malignant Glioma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   Wilms Tumor
    Intervention:   Drug: Olaparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
    NCT03220035
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Ependymoma;   Ewing Sarcoma;   Hepatoblastoma;   Langerhans Cell Histiocytosis;   Malignant Germ Cell Tumor;   Malignant Glioma;   Osteosarcoma;   Peripheral Primitive Neuroectodermal Tumor;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Safety and Efficacy of 2 Treatment Regimens of Aztreonam for Inhalation Solution in Children With Cystic Fibrosis and New Onset Pseudomonas Aeruginosa Infection
    NCT03219164
    Conditions:   Pseudomonas Aeruginosa Respiratory Tract Infection;   Cystic Fibrosis
    Interventions:   Drug: AZLI;   Drug: Placebo
    Sponsor:   Gilead Sciences
    Recruiting
  • Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
    NCT03213665
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   EZH2 Gene Mutation;   Low Grade Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Hodgkin Lymphoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Hodgkin Lymphoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   SMARCA4 Gene Inactivation;   SMARCB1 Gene Inactivation;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Tazemetostat
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
    NCT03213652
    Conditions:   Advanced Malignant Solid Neoplasm;   ALK Fusion Protein Expression;   ALK Gene Mutation;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   ROS1 Fusion Positive;   ROS1 Gene Mutation
    Interventions:   Drug: Ensartinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
    NCT03210714
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Low Grade Glioma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
    Interventions:   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma
    NCT03057626
    Conditions:   Recurrent Neuroblastoma;   Stage 2A Neuroblastoma;   Stage 2B Neuroblastoma;   Stage 3 Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
    NCT03057054
    Condition:   Malignant Neoplasm
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Lactobacillus plantarum strain 299;   Biological: Lactobacillus plantarum strain 299v;   Other: Placebo
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia
    NCT03025698
    Condition:   Aplastic Anemia
    Interventions:   Drug: Eltrombopag;   Drug: hATG;   Drug: CsA
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • A Study of the Relationship of Psychosocial Function With Mood Symptoms in Offspring of Parents With Bipolar Disorder
    NCT03017781
    Condition:   Bipolar Disorder
    Intervention:  
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
    NCT02900976
    Conditions:   EBV-Related Post-Transplant Lymphoproliferative Disorder;   Monomorphic Post-Transplant Lymphoproliferative Disorder;   Polymorphic Post-Transplant Lymphoproliferative Disorder;   Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder;   Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder;   Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder;   Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
    Interventions:   Biological: Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes;   Biological: Rituximab
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Neuropsychological and Behavioral Testing in Younger Patients With Cancer
    NCT00772200
    Conditions:   Childhood Malignant Neoplasm;   Cognitive Side Effects of Cancer Therapy
    Interventions:   Procedure: Cognitive Assessment;   Other: Quality-of-Life Assessment
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
    NCT02772965
    Condition:   Pediatric Crohn's Disease
    Interventions:   Drug: Methotrexate;   Other: Sugar pill (placebo)
    Sponsors:   University of North Carolina, Chapel Hill;   Patient-Centered Outcomes Research Institute;   ImproveCareNow (ICN);   The Leona M. and Harry B. Helmsley Charitable Trust;   Children's Hospital Medical Center, Cincinnati;   Grifols Diagnostics Solutions, Inc;   National Institutes of Health (NIH);   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
    Recruiting
  • Neuroblastoma Maintenance Therapy Trial
    NCT02679144
    Condition:   Neuroblastoma
    Intervention:   Drug: Difluoromethylornithine (DFMO)
    Sponsors:   Giselle Sholler;   KC Pharma;   Beat NB Cancer Foundation
    Recruiting
  • Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study
    NCT02303431
    Conditions:   Deep Vein Thrombosis;   Venous Thromboembolism
    Interventions:   Drug: Edoxaban low dose;   Drug: Edoxaban high dose
    Sponsor:   Daiichi Sankyo, Inc.
    Recruiting
  • LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
    NCT02205762
    Condition:   Langerhans Cell Histiocytosis
    Interventions:   Drug: Prednisone;   Drug: Vinblastine;   Drug: mercaptopurine;   Drug: INDOMETHACIN;   Drug: Methotrexate;   Drug: Cytosine Arabinoside;   Drug: 2-chlorodeoxyadenosine;   Procedure: hematopoietic stem cell transplantation (RIC-HSCT);   Biological: Intravenous immunoglobulin
    Sponsors:   North American Consortium for Histiocytosis;   Histiocyte Society
    Recruiting
  • Consent for Use of Stored Patient Specimens for Future Testing
    NCT00031408
    Condition:   HIV Infections
    Intervention:  
    Sponsors:   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting
  • Evaluation of the Duration of Therapy for Thrombosis in Children
    NCT00687882
    Condition:   Venous Thrombosis
    Interventions:   Other: Shortened duration (6 weeks) of anticoagulant therapy;   Other: Conventional duration (3 months) of anticoagulant therapy;   Other: No Intervention
    Sponsors:   Johns Hopkins All Children's Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting
  • The Pediatric Anesthesia Quality Improvement Project
    NCT00674388
    Conditions:   Surgery;   Anesthesia;   Children
    Intervention:  
    Sponsors:   The Society for Pediatric Anesthesia;   Children's Hospital Medical Center, Cincinnati;   Monroe Carell Jr. Children's Hospital at Vanderbilt;   Seattle Children's Hospital;   Boston Children’s Hospital;   Emory-Children's Center;   Texas Children's Hospital;   Johns Hopkins University;   Children's Hospital Los Angeles;   Morgan Stanley Children's Hospital of New York;   Children's Hospital of Philadelphia;   Ann & Robert H Lurie Children's Hospital of Chicago;   University of Pittsburgh;   Phoenix Children's Hospital;   University of Michigan;   Children's National Health System;   Nationwide Children's Hospital;   Arkansas Children's Hospital Research Institute;   Children's Hospital Colorado;   St. Jude Children's Research Hospital;   Cook Children's Health Care System;   SSM Cardinal Glennon Children's Medical Center;   The Children's Hospital at Montefiore;   Children's Medical Center Dallas;   Lucile Packard Children's Hospital Stanford;   Alfred I. duPont Hospital for Children;   Johns Hopkins All Children's Hospital;   Children's Hospitals and Clinics of Minnesota;   Oakland Medical Center;   Children's Hospital and Medical Center, Omaha, Nebraska;   Medical University of South Carolina;   Akron Children's Hospital;   Women & Children's Hospital of Buffalo;   Dayton Children's Hospital;   Riley Children's Hospital;   Cleveland Clinic Children's Hospital;   Penn State Hershey Children's Hospital
    Recruiting
  • Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders
    NCT03335488
    Condition:   Urea Cycle Disorder
    Interventions:   Drug: RAVICTI;   Drug: NaPBA
    Sponsor:   Horizon Therapeutics, LLC
    Recruiting
  • Prevention of Urinary Stones With Hydration
    NCT03244189
    Condition:   Urinary Stones
    Interventions:   Behavioral: Fluid prescription;   Behavioral: Financial incentive;   Behavioral: Structured Problem Solving
    Sponsors:   Duke University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting
  • Zoliflodacin in Uncomplicated Gonorrhoea
    NCT03959527
    Condition:   Gonorrhea
    Interventions:   Drug: zoliflodacin;   Drug: ceftriaxone;   Drug: azithromycin
    Sponsor:   Global Antibiotics Research and Development Partnership
    Recruiting
  • Pravastatin to Prevent Preeclampsia
    NCT03944512
    Conditions:   Preeclampsia;   Obstetric Labor Complications;   Hypertension in Pregnancy
    Interventions:   Drug: Pravastatin;   Other: Placebo
    Sponsors:   The George Washington University Biostatistics Center;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting
  • The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
    NCT03805789
    Condition:   Graft Versus Host Disease
    Interventions:   Biological: Alpha-1 antitrypsin (AAT);   Biological: Placebo
    Sponsor:   CSL Behring
    Recruiting
  • The Global cVAD Study
    NCT04136392
    Condition:   Cardiovascular Diseases
    Intervention:   Device: ABIOMED, Inc. hemodynamic support devices
    Sponsors:   Abiomed Inc.;   Beth Israel Deaconess Medical Center;   Yale University
    Recruiting
  • Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
    NCT04099251
    Condition:   Melanoma
    Interventions:   Biological: Nivolumab;   Other: Placebo
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • A Randomized Trial of Pessary in Singleton Pregnancies With a Short Cervix
    NCT02901626
    Conditions:   Short Cervix;   Preterm Delivery
    Intervention:   Device: Pessary
    Sponsors:   The George Washington University Biostatistics Center;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting
  • A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)
    NCT04058353
    Condition:   Cystic Fibrosis
    Interventions:   Drug: ELX/TEZ/IVA;   Drug: IVA;   Drug: TEZ/IVA
    Sponsor:   Vertex Pharmaceuticals Incorporated
    Recruiting
  • NeuMoDx PrEDiCTiNG Study Evaluation Plan
    NCT03970850
    Conditions:   Chlamydia Trachomatis Infection;   Neisseria Gonorrheae Infection
    Interventions:   Diagnostic Test: NeuMoDx CT/NG Assay;   Diagnostic Test: FDA-cleared NAATs
    Sponsors:   NeuMoDx Molecular, Inc.;   NAMSA
    Recruiting
  • A Study to Compare US Marketed Pancrelipase Drug Product With Drug Product Manufactured With a Modernized Process at an Alternate Manufacturing Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis.
    NCT03924947
    Condition:   Cystic Fibrosis
    Intervention:   Drug: Pancrelipase
    Sponsor:   AbbVie
    Recruiting
  • Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation
    NCT03904134
    Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Non-hodgkin Lymphoma;   Hodgkin Lymphoma;   Acquired Aplastic Anemia;   Sickle Cell Disease
    Intervention:   Other: Donor Search Prognosis Score
    Sponsors:   Center for International Blood and Marrow Transplant Research;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network;   National Marrow Donor Program;   Medical College of Wisconsin
    Recruiting
  • Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
    NCT03893448
    Conditions:   Pneumococcal Infections;   Pneumococcal Vaccines
    Interventions:   Biological: V114;   Biological: Prevnar 13™;   Biological: RotaTeq™;   Biological: Pentacel™;   Biological: RECOMBIVAX HB™;   Biological: VAQTA™;   Biological: M-M-R™;   Biological: VARIVAX™;   Biological: HIBERIX™
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  • TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
    NCT02657005
    Condition:   Sarcoma, Ewing
    Intervention:   Drug: TK216
    Sponsor:   Oncternal Therapeutics, Inc
    Recruiting
  • RHAPSODY Phase 3 Study to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects With Recurrent Pericarditis
    NCT03737110
    Condition:   Recurrent Pericarditis
    Interventions:   Drug: Rilonacept;   Drug: Placebo
    Sponsor:   Kiniksa Pharmaceuticals, Ltd.
    Recruiting
  • ACURATE IDE: Safety and Efficacy Study of Acurate Valve for Transcatheter Aortic Valve Replacement
    NCT03735667
    Condition:   Aortic Stenosis
    Interventions:   Device: ACURATE neo2™ Transfemoral TAVR System;   Device: Medtronic CoreValve TAVR System;   Device: Edwards SAPIEN 3 TAVR System
    Sponsor:   Boston Scientific Corporation
    Recruiting
  • PF-06651600 for the Treatment of Alopecia Areata
    NCT03732807
    Condition:   Alopecia Areata
    Interventions:   Drug: PF-06651600 Induction Dose;   Drug: PF-06651600 Maintenance Dose #1;   Drug: PF-06651600 Maintenance Dose #2;   Drug: PF-06651600 Maintenance Dose #3;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting
  • Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations
    NCT03316560
    Condition:   X-Linked Retinitis Pigmentosa
    Intervention:   Biological: rAAV2tYF-GRK1-RPGR
    Sponsor:   Applied Genetic Technologies Corp
    Recruiting
  • Open-Label Extension Study of Diazoxide Choline in Patients With Prader-Willi Syndrome
    NCT03714373
    Condition:   Prader-Willi Syndrome
    Intervention:   Drug: DCCR
    Sponsor:   Soleno Therapeutics, Inc.
    Recruiting
  • Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
    NCT03712202
    Conditions:   Ann Arbor Stage I Hodgkin Lymphoma;   Ann Arbor Stage I Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IA Hodgkin Lymphoma;   Ann Arbor Stage IB Hodgkin Lymphoma;   Ann Arbor Stage II Hodgkin Lymphoma;   Ann Arbor Stage II Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage II Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage II Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IIA Hodgkin Lymphoma;   Ann Arbor Stage IIB Hodgkin Lymphoma;   Classic Hodgkin Lymphoma;   Lymphocyte-Rich Classic Hodgkin Lymphoma
    Interventions:   Drug: Bleomycin;   Drug: Brentuximab Vedotin;   Drug: Dacarbazine;   Drug: Doxorubicin;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Vinblastine
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting
  • Surveillance HeartCare® Outcomes Registry
    NCT03695601
    Condition:   Heart Transplant Rejection
    Intervention:   Other: Standard of Care
    Sponsor:   CareDx
    Recruiting
  • A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study
    NCT03691662
    Condition:   Glaucoma and Ocular Hypertension
    Interventions:   Drug: DE-117 Ophthalmic Solution;   Drug: Timolol Maleate Ophthalmic Solution 0.5%
    Sponsor:   Santen Inc.
    Recruiting
  • A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis
    NCT03653026
    Condition:   Ulcerative Colitis (UC)
    Interventions:   Drug: Upadacitinib (ABT-494);   Drug: Placebo
    Sponsor:   AbbVie
    Recruiting
  • Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
    NCT03646123
    Condition:   Hodgkin Lymphoma
    Interventions:   Drug: brentuximab vedotin;   Drug: doxorubicin;   Drug: vinblastine;   Drug: dacarbazine;   Drug: G-CSF;   Drug: nivolumab
    Sponsor:   Seattle Genetics, Inc.
    Recruiting
  • A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
    NCT03607422
    Condition:   Atopic Dermatitis
    Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib
    Sponsor:   AbbVie
    Recruiting
  • Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)
    NCT03603288
    Condition:   Duchenne Muscular Dystrophy
    Intervention:   Drug: idebenone 150 mg film-coated tablets
    Sponsor:   Santhera Pharmaceuticals
    Recruiting
  • Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)- Measure Up 1
    NCT03569293
    Condition:   Atopic Dermatitis
    Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib
    Sponsor:   AbbVie
    Recruiting
  • A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)
    NCT03565900
    Condition:   Pneumococcal Infections
    Interventions:   Biological: V114;   Biological: Prevnar 13™;   Biological: PNEUMOVAX™23
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  • Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma
    NCT03495921
    Conditions:   Ewing Sarcoma;   Ewing Family of Tumors;   Ewing's Tumor Metastatic;   Ewing's Sarcoma Metastatic;   Ewing's Tumor Recurrent;   Rare Diseases;   Sarcoma;   Neoplasms, Connective and Soft Tissue;   Neoplasms by Histologic Type;   Neoplasms, Bone Tissue;   Neoplasms, Connective Tissue;   Sarcoma, Ewing;   Neoplasms
    Interventions:   Biological: Vigil;   Drug: Irinotecan;   Drug: Temozolomide
    Sponsor:   Gradalis, Inc.
    Recruiting
  • Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
    NCT03493685
    Condition:   Focal Segmental Glomerulosclerosis
    Interventions:   Drug: sparsentan;   Drug: irbesartan
    Sponsor:   Retrophin, Inc.
    Recruiting
  • A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
    NCT03464097
    Condition:   Crohn Disease
    Interventions:   Drug: Ozanimod;   Other: Placebo
    Sponsor:   Celgene
    Recruiting
  • Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
    NCT03451045
    Condition:   Cystic Fibrosis
    Interventions:   Drug: Lenabasum 20 mg;   Drug: Lenabasum 5 mg;   Other: Placebo
    Sponsors:   Corbus Pharmaceuticals Inc.;   Cystic Fibrosis Foundation
    Recruiting
  • Evaluation of Safety and Efficacy of Brimonidine Tartrate Ophthalmic Suspension
    NCT03450629
    Conditions:   Open Angle Glaucoma;   Ocular Hypertension
    Interventions:   Drug: Brimonidine Tartrate Ophthalmic Suspension;   Drug: Brimonidine Tartrate Ophthalmic Solution
    Sponsor:   Sun Pharma Advanced Research Company Limited
    Recruiting
  • A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome
    NCT03440814
    Condition:   Prader-Willi Syndrome
    Interventions:   Drug: DCCR;   Drug: Placebo for DCCR
    Sponsor:   Soleno Therapeutics, Inc.
    Recruiting
  • Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
    NCT03440385
    Condition:   Crohn Disease
    Interventions:   Drug: Ozanimod;   Other: Placebo
    Sponsor:   Celgene
    Recruiting
  • Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
    NCT03440372
    Condition:   Crohn Disease
    Interventions:   Drug: Ozanimod;   Other: Placebo
    Sponsor:   Celgene
    Recruiting
  • Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
    NCT03435796
    Condition:   Neoplasms
    Intervention:   Genetic: Gene-modified (GM) T cell therapy
    Sponsor:   Celgene
    Recruiting
  • Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
    NCT03422822
    Condition:   Dermatitis, Atopic
    Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting
  • A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors
    NCT03417245
    Conditions:   Hemophilia A;   Hemophilia B
    Interventions:   Drug: fitusiran;   Drug: factor VIII or factor IX
    Sponsor:   Genzyme, a Sanofi Company
    Recruiting
  • A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy
    NCT03398148
    Condition:   Ulcerative Colitis (UC)
    Interventions:   Drug: risankizumab IV;   Drug: placebo for risankizumab;   Drug: risankizumab SC
    Sponsor:   AbbVie
    Recruiting
  • A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065
    NCT03398135
    Condition:   Ulcerative Colitis (UC)
    Interventions:   Drug: risankizumab;   Drug: placebo for risankizumab
    Sponsor:   AbbVie
    Recruiting
  • A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
    NCT03251118
    Conditions:   Inflammatory Bowel Diseases;   Crohn's Disease;   Ulcerative Colitis;   Indeterminate Colitis
    Intervention:  
    Sponsor:   Target PharmaSolutions, Inc.
    Recruiting
  • A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients
    NCT03181932
    Conditions:   MRSA;   Cystic Fibrosis
    Interventions:   Drug: Vancomycin inhalation powder;   Drug: Placebo inhalation powder
    Sponsor:   Savara Inc.
    Recruiting
  • Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
    NCT03157128
    Conditions:   Non-Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Any Solid Tumor
    Intervention:   Drug: LOXO-292
    Sponsor:   Loxo Oncology, Inc.
    Recruiting
  • A Study in Participants Previously Enrolled in a Genentech− and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
    NCT03148418
    Condition:   Cancer
    Intervention:   Drug: Atezolizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery
    NCT03148275
    Conditions:   Epithelioid Hemangioendothelioma;   Locally Advanced Epithelioid Hemangioendothelioma;   Metastatic Epithelioid Hemangioendothelioma
    Interventions:   Other: Questionnaire Administration;   Drug: Trametinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease
    NCT03105128
    Condition:   Crohn's Disease
    Interventions:   Drug: placebo for risankizumab;   Drug: risankizumab IV;   Drug: risankizumab SC
    Sponsor:   AbbVie
    Recruiting
  • A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
    NCT03104413
    Condition:   Crohn's Disease
    Interventions:   Drug: placebo for risankizumab IV;   Drug: risankizumab SC;   Drug: risankizumab IV
    Sponsor:   AbbVie
    Recruiting
  • A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
    NCT03093116
    Conditions:   Locally Advanced Solid Tumors;   Metastatic Solid Tumors
    Intervention:   Drug: Oral repotrectinib (TPX-0005)
    Sponsor:   Turning Point Therapeutics, Inc.
    Recruiting
  • DCM Precision Medicine Study
    NCT03037632
    Condition:   Idiopathic Dilated Cardiomyopathy
    Intervention:   Behavioral: Family Heart Talk Booklet
    Sponsors:   Ray Hershberger;   National Heart, Lung, and Blood Institute (NHLBI);   National Human Genome Research Institute (NHGRI)
    Recruiting
  • Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
    NCT02931539
    Condition:   Cytomegalovirus (CMV)
    Interventions:   Drug: Maribavir;   Drug: Ganciclovir;   Drug: Valganciclovir;   Drug: Foscarnet;   Drug: Cidofovir
    Sponsor:   Shire
    Recruiting
  • Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome
    NCT02834793
    Condition:   Lennox-Gastaut Syndrome (LGS)
    Interventions:   Drug: Placebo;   Drug: Perampanel
    Sponsor:   Eisai Inc.
    Recruiting
  • A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)
    NCT02815891
    Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis
    Intervention:  
    Sponsor:   Target PharmaSolutions, Inc.
    Recruiting
  • An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US
    NCT02783651
    Condition:   Relapsed/Refractory Acute Lymphoblastic Leukemia
    Intervention:   Other: Other
    Sponsor:   Amgen
    Recruiting
  • Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard Umbilical Cord Blood in Patients With Leukemia, Lymphoma, and Myelodysplastic Syndrome (MDS)
    NCT02730299
    Conditions:   Hematological Malignancies;   Acute Lymphoblastic Leukemia (ALL);   Acute Myelogenous Leukemia (AML);   Chronic Myelogenous Leukemia (CML);   Myelodysplastic Syndrome (MDS);   Lymphoma;   Acute Leukemia
    Interventions:   Drug: NiCord® (omidubicel);   Other: Cord Blood Unit
    Sponsor:   Gamida Cell ltd
    Recruiting
  • Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)
    NCT00315380
    Conditions:   Eosinophilic Granulomatosis With Polyangiitis;   Churg-Strauss Syndrome
    Intervention:  
    Sponsors:   University of Pennsylvania;   Office of Rare Diseases (ORD);   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);   Rare Diseases Clinical Research Network
    Recruiting
  • A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    NCT02576431
    Condition:   Solid Tumors Harboring NTRK Fusion
    Intervention:   Drug: BAY2757556 (Larotrectinib, Vitrakvi)
    Sponsor:   Bayer
    Recruiting
  • A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix
    NCT02518594
    Condition:   Short Cervical Length
    Interventions:   Drug: Vaginal progesterone;   Drug: Placebo;   Device: Arabin Pessary
    Sponsors:   The George Washington University Biostatistics Center;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting
  • Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis
    NCT02435992
    Condition:   Ulcerative Colitis
    Interventions:   Drug: RPC1063;   Drug: Placebo
    Sponsor:   Celgene
    Recruiting
  • Phenotype, Genotype & Biomarkers in ALS and Related Disorders
    NCT02327845
    Conditions:   Amyotrophic Lateral Sclerosis;   Frontotemporal Dementia;   Primary Lateral Sclerosis;   Hereditary Spastic Paraplegia;   Progressive Muscular Atrophy;   Multisystem Proteinopathy
    Intervention:  
    Sponsors:   University of Miami;   National Institute of Neurological Disorders and Stroke (NINDS);   National Center for Advancing Translational Science (NCATS);   St. Jude Children's Research Hospital;   ALS Association
    Recruiting
  • Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement
    NCT02202434
    Condition:   Aortic Stenosis
    Interventions:   Device: Lotus Valve System;   Device: CoreValve/Evolut R Transcatheter Aortic Valve Replacement System;   Device: LOTUS Edge Valve System
    Sponsor:   Boston Scientific Corporation
    Recruiting
  • A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.
    NCT01792726
    Condition:   Early Breast Cancer
    Intervention:   Radiation: Boost to the tumour bed
    Sponsors:   University College, London;   National Institute for Health Research, United Kingdom
    Recruiting
  • Long Term Follow Up Protocol for NiCord®/CordIn™ Patients
    NCT02039557
    Condition:   Patients Transplanted With NiCord/CordIn
    Intervention:   Genetic: NiCord®/CordIn™
    Sponsor:   Gamida Cell ltd
    Recruiting
  • A Registry for Patients With Chronic Hypoparathyroidism
    NCT01922440
    Condition:   Chronic Hypoparathyroidism
    Intervention:   Drug: Combination product (Natpara) and drug or supplements [Disease and drug registry]
    Sponsor:   Shire
    Recruiting
  • Longitudinal Study of the Porphyrias
    NCT01561157
    Conditions:   Acute Porphyrias;   Cutaneous Porphyrias
    Intervention:  
    Sponsor:   Icahn School of Medicine at Mount Sinai
    Recruiting
  • Product Surveillance Registry
    NCT01524276
    Conditions:   Cardiac Rhythm Disorders;   Urological Disorders;   Neurological Disorders;   Cardiovascular Disorders;   Digestive Disorders;   Intracranial Aneurysm;   Mechanical Circulatory Support
    Intervention:  
    Sponsor:   Medtronic
    Recruiting
  • One-Time DNA Study for Vasculitis
    NCT01241305
    Conditions:   Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss);   Giant Cell Arteritis;   Granulomatosis With Polyangiitis (Wegener's);   Microscopic Polyangiitis;   Polyarteritis Nodosa;   Takayasu's Arteritis
    Intervention:  
    Sponsors:   University of Pennsylvania;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);   Office of Rare Diseases (ORD);   Rare Diseases Clinical Research Network
    Recruiting
  • Natural History Study of SCID Disorders
    NCT01186913
    Conditions:   Severe Combined Immunodeficiency (SCID);   Leaky SCID;   Omenn Syndrome;   Reticular Dysgenesis;   ADA SCID;   XSCID
    Intervention:  
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Primary Immune Deficiency Treatment Consortium (PIDTC);   Office of Rare Diseases (ORD);   National Center for Advancing Translational Science (NCATS)
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC